InMode Ltd vs QXO Inc. Common Stock — how do they compare? InMode Ltd trades at $14.29 (market cap $823.46M), while QXO Inc. Common Stock trades at $10.37 (market cap $11.43B). The key difference: QXO Inc. Common Stock is far larger — about 13.9× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and QXO Inc. Common Stock for 0 Days on average.
| INMD | QXO | |
|---|---|---|
Market Cap | $823.46M | $11.43B |
Volume | 427,627 | 21,645,941 |
Sector | Health | Industrials |
52-Week High | $16.62 | $27.07 |
52-Week Low | $12.76 | $10.33 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $326.79M | $16.75B |
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.305, showing minimal daily movement with a 0.03% gain. The stock maintains a bullish technical signal despite mixed indicators, with RSI suggesting mild overbought conditions. Fundamentally, the company demonstrates strong profitability with 76.52% gross margins and 20.69% net income margins, though 2026 guidance shows potential margin compression. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
The investment outlook balances attractive valuation metrics (P/E of 11.83, EV/EBITDA of 4.68) against cyclical industry headwinds and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings, while technicals suggest near-term consolidation around current levels. Key risks include US platform sales decline and execution on international growth strategy.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →